Michael Conry,Irina Ostrovnaya,Yelena Kemel,Saloni Sinha,Linda B Baughn,Brian Avery,Kylee Maclachlan,Victoria Groner,Lauren Banaszak,Aaron Norman,Nicholas J Boddicker,Alyssa Clay-Gilmour,Shaji Kumar,Ellen Kim,Sita Dandiker,Mitul Waghmare,Susan Slager,Douglas W Sborov,Judy Garber,Elizabeth E Brown,Michelle Hildebrandt,Parameshwaran Hari,Nicola Camp,Celine Vachon,Saad Usmani,Kenneth Offit,Vijai Joseph
{"title":"Multiple myeloma risk linked to DNA damage response genes.","authors":"Michael Conry,Irina Ostrovnaya,Yelena Kemel,Saloni Sinha,Linda B Baughn,Brian Avery,Kylee Maclachlan,Victoria Groner,Lauren Banaszak,Aaron Norman,Nicholas J Boddicker,Alyssa Clay-Gilmour,Shaji Kumar,Ellen Kim,Sita Dandiker,Mitul Waghmare,Susan Slager,Douglas W Sborov,Judy Garber,Elizabeth E Brown,Michelle Hildebrandt,Parameshwaran Hari,Nicola Camp,Celine Vachon,Saad Usmani,Kenneth Offit,Vijai Joseph","doi":"10.1186/s13045-025-01776-1","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nDNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM).\r\n\r\nMETHODS\r\nHerein, we analyzed disease associations of pathogenic variations in nine putative candidate genes using 3 446 MM cases and 323 233 cancer-free controls.\r\n\r\nRESULTS\r\nIncreased MM risk was found to be associated with inherited rare pathogenic mutations in TP53, ATM, CHEK2, KDM1A, and ARID1A, with an enrichment of these variants among individuals with early onset or family history of MM. Individuals with TP53 or ATM germline mutations are also likely to have worse overall survival.\r\n\r\nCONCLUSIONS\r\nOur results suggest expansion of the phenotypic spectrum of some of these DDRG to include MM. The identification of these germline predisposition genes opens the avenue for targeted screening of higher risk individuals especially those with young-onset or a family history of plasma cell gammopathies.","PeriodicalId":16023,"journal":{"name":"Journal of Hematology & Oncology","volume":"32 1","pages":""},"PeriodicalIF":47.8000,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hematology & Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13045-025-01776-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND
DNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM).
METHODS
Herein, we analyzed disease associations of pathogenic variations in nine putative candidate genes using 3 446 MM cases and 323 233 cancer-free controls.
RESULTS
Increased MM risk was found to be associated with inherited rare pathogenic mutations in TP53, ATM, CHEK2, KDM1A, and ARID1A, with an enrichment of these variants among individuals with early onset or family history of MM. Individuals with TP53 or ATM germline mutations are also likely to have worse overall survival.
CONCLUSIONS
Our results suggest expansion of the phenotypic spectrum of some of these DDRG to include MM. The identification of these germline predisposition genes opens the avenue for targeted screening of higher risk individuals especially those with young-onset or a family history of plasma cell gammopathies.
期刊介绍:
The Journal of Hematology & Oncology, an open-access journal, publishes high-quality research covering all aspects of hematology and oncology, including reviews and research highlights on "hot topics" by leading experts.
Given the close relationship and rapid evolution of hematology and oncology, the journal aims to meet the demand for a dedicated platform for publishing discoveries from both fields. It serves as an international platform for sharing laboratory and clinical findings among laboratory scientists, physician scientists, hematologists, and oncologists in an open-access format. With a rapid turnaround time from submission to publication, the journal facilitates real-time sharing of knowledge and new successes.